O'Neill Institute  |  July 7, 2025

Read the Publication

This Equitable Access Review (hereafter the Review) of CEPI’s Chikungunya vaccine development agreements was commissioned by CEPI in 2024 as an external review of how equitable access has been incorporated into CEPI’s partnerships and planning leading to the licensure of the first Chikungunya vaccine by the US FDA in 2023 and other candidates now in late stage development. This Review aims to evaluate and generate lessons learned on how CEPI performed against its commitment to equitable access, and how these learnings may contribute to further enhance CEPI’s agreements and activities moving forward. The Center for Transformational Health Law (CTHL) at the O’Neill Institute for National and Global Law at Georgetown University, was selected to undertake the Review.

Latest publications See All

Report

October 14, 2025

Charles Holmes Maggie Little, Ph.D.; Heidi Weimer, J.D., MPH, LL.M; Dylan Green, MPH; Alicia Patterson, Ph.D.; Jonathan Healey; Sydney Luken; Janet Tatenda Bhila; Aleny Couto, MD; Shona Dalal, PhD; Will Fleisher, PhD; Jen Gennai; Rayid Ghani; Peter Godfrey-Faussett; Melissa Goldstein, JD; Kathy Hageman, PhD, MPH; Nina Hasen, PhD; Micheal Ighodaro; Thoko Kalua, MBBS, MSc; Jennifer Miller, PhD; Yogan Pillay, PhD; Anton Pozniak, MD; Miriam Rabkin, MD, MPH; David Ribes, PhD; Lisa Singh, PhD